Metaplastic breast cancer: A review.

Clinical management Clinical outcomes Epithelial-to-mesenchymal transition Immunotherapy Metaplastic breast cancer Pathology Targeted therapy

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 17 07 2022
revised: 19 12 2022
accepted: 20 01 2023
pubmed: 26 1 2023
medline: 8 2 2023
entrez: 25 1 2023
Statut: ppublish

Résumé

Metaplastic breast cancer (MpBC) is an uncommon aggressive malignancy that is associated with a poor prognosis. Due to its rarity, the relationships between the clinical and pathological features of MpBC, treatment approach, and clinical outcomes remain underexplored. In the following review article, we synthesize the existing data on the clinical, pathological and genomic features, management, and outcomes of MpBC. We also identify potential targets for future clinical trials.

Identifiants

pubmed: 36696934
pii: S1040-8428(23)00012-4
doi: 10.1016/j.critrevonc.2023.103924
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103924

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest We declare no competing interests. B: CT chest with contrast (axial, left; coronal, right) of a second patient also depicts a large well-defined mass involving the pleura and minor fissure, with morphology similar to metastatic sarcomatous nodules.

Auteurs

Horatio R Thomas (HR)

Department of Radiation Oncology, University of California, San Francisco, United States. Electronic address: horatio.thomas@ucsf.edu.

Bonnie Hu (B)

Department of Radiation Oncology, Massachusetts General Hospital, United States.

Baris Boyraz (B)

Department of Pathology, Massachusetts General Hospital, United States.

Andrew Johnson (A)

Department of Radiation Oncology, Massachusetts General Hospital, United States.

Veerle I Bossuyt (VI)

Department of Pathology, Massachusetts General Hospital, United States.

Laura Spring (L)

Department of Medicine, Division of Medical Oncology, Massachusetts General Hospital, United States.

Rachel B Jimenez (RB)

Department of Radiation Oncology, Massachusetts General Hospital, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH